Poor
Not Aligned
Patient Risk:
Low
Summary
Multiple claims make functional assertions about excipients (stabilization/release control) that are not supported by the provided FDA label section, and several claims are marked absent from the label or overbroad (e.g., country-specific differences; comparisons with Wegovy).
Category Scores
Accurate Statements
The exact excipients in Ozempic can vary by formulation and pack strength.
Supported by label listing different inactive ingredients across strengths and presentations in 11 DESCRIPTION.
Excipients in Ozempic can vary between pen and presentation.
Supported by label listing different inactive ingredients for the prefilled pen vs the single-dose syringe in 11 DESCRIPTION.
Unsupported Statements
Ozempic (semaglutide) contains inactive ingredients (excipients) that help stabilize the medicine.
11 DESCRIPTION attributes stabilization against DPP-4 degradation to semaglutide modification (position 8) and lists inactive ingredients, but does not state excipients help stabilize.
Ozempic (semaglutide) contains inactive ingredients (excipients) that control how it is released in the injection.
11 DESCRIPTION does not state any role of excipients in release control.
The inactive ingredients list for Ozempic is available in the package insert for the specific Ozempic product.
11 DESCRIPTION provides ingredient lists for specific presentations, but does not explicitly claim availability as a 'package insert for the specific product' in the manner stated.
Excipients lists can differ by country and by product presentation for Ozempic.
11 DESCRIPTION provides no information about country-specific differences.
The exact Ozempic excipients can be found in the 'Inactive ingredients' section of the prescribing information for the exact Ozempic package.
11 DESCRIPTION supports listing inactive ingredients for specific presentations, but does not explicitly direct readers to an 'Inactive ingredients' section of the prescribing information or 'exact package' as stated.
Ozempic and Wegovy both use semaglutide.
No support provided in the supplied label section (11 DESCRIPTION) and no citations are available for this cross-product comparison.
Ozempic and Wegovy have different formulations.
No support provided in the supplied label section (11 DESCRIPTION) and no citations are available for this comparison.
Because Ozempic and Wegovy formulations are different, their inactive ingredient lists can differ as well.
No support provided in the supplied label section; the causal relationship and claim are not substantiated by the provided label.
Patients with excipient sensitivities may need to know which branded product and which pen strength is being used.
11 DESCRIPTION does not include patient guidance about excipient sensitivities or the specific need to know brand/pen strength.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
No evaluation was performed of other label areas (e.g., boxed warnings, contraindications, Warnings/precautions, adverse reactions, drug interactions), though none of the submitted claims referenced those sections.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The main problems are informational/attribution errors about excipient roles and unsupported cross-product or country-specific claims, rather than direct dosing or contraindication errors. Still, patient-facing statements about excipient sensitivities and package-specific ingredient sourcing are not supported by the provided label section.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Functionally specific claims about excipients (stabilization and release control) are not supported by the provided FDA label section; several other statements are unsupported/absent (country differences, Wegovy comparisons, patient sensitivity guidance, and package-insert/section phrasing).
Suggested Improvement
Limit claims to what 11 DESCRIPTION explicitly states: Ozempic is a semaglutide injection and the inactive ingredients differ between the prefilled pen and single-dose syringe and by listed strengths; remove or rephrase any functional assertions about excipients and any unsupported country/Wegovy/patient-sensitivity or 'Inactive ingredients section' sourcing language.